Teva Pharmaceutical Industries Ltd.'s decision last year to divest its R&D oncology assets ended up being Ignyta Inc.'s gain, with the latter picking up rights to four clinical and preclinical compounds in an asset purchase deal that triples the size of its pipeline and sets the stage for master protocol-designed trials of multiple targeted therapies.